Table 1.
Demographics of patients included into the study
| # of patients |
Age, years |
Gender | Race | Allograft | |||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD |
Male | Female | Caucasian | African- American |
Others | CAD | LD | ||
| Group1 | 14 | 38.9±8.5 | 10 | 4 | 7 | 6 | 1 | 14 | n/a |
| Group2 | 62 | 55.8±10.2 | 35 | 27 | 38 | 20 | 4 | 30 | 32 |
| Group3 | 43 | 47.9±12.4 | 25 | 18 | 40 | 3 | 0 | 13 | 30 |
| Group4 | 18 | 42.6±14.4 | 9 | 9 | 14 | 2 | 2 | 9 | 9 |
| Group5 | 90 | 47.8±12.9 | 51 | 39 | 66 | 19 | 5 | 46 | 44 |
| Total | 227 | 49.0±12.8 | 130 | 97 | 165 | 50 | 12 | 112 | 115 |
| Healthy donors | 60 | 43.1±11.0 | 11 | 49 | 51 | 7 | 2 | n/a | n/a |
Group 1 – patients with end stage kidney disease secondary to diabetic nephropathy because of diabetes mellitus type I, who received kidney/pancreas simultaneous allografts;
Group 2 - patients with end stage kidney disease secondary to diabetic nephropathy because of diabetes mellitus type I or type II, who received kidney allograft only;
Group 3 – patients with end stage kidney disease secondary to congenital kidney disease or acquired obstructive nephropathy;
Group 4 – patients with end stage kidney disease secondary to immune-complex mediated glomerulonephritides (IgA nephropathy, membranous glomerulonephritis, lupus nephritis);
Group 5 – patients with unknown/unclassified end stage kidney disease.
CAD – cadaveric donor renal allograft; LD – living donor renal allograft.
Data are present as number of patients or mean ±SD, when applicable.